The made-in-Italy fast-track acceleration program dedicated to projects in life science

ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.

The call for ideas is open until 16 July 2017 and it covers four main areas of interest:

  • Drug delivery systems (systems that allow better drug delivery either through particles or devices);
  • Open source prototyping: medical devices, biomarkers, diagnostics (Instruments and devices that allow safe and effective treatment, rehabilitation, prevention and diagnosis of diseases);
  • Wearables and digital health (technological solutions through wearable devices that improve the cure of diseases; technological platforms or mobile applications that offer new solutions to improve patient's health)
  • Big data (projects related to the data analysis and solutions to improve medical treatment, develop personalized medicine, identify new markers for early diagnosis and that reduce healthcare costs).

"For many years ZCube has been committed to developing partnerships in the field of scientific research through an open approach which aims at establishing relationships with international researchers, centers of excellence and universities around the world," declares Elena Zambon, President of Zambon Spa. "Open Accelerator is an evolution of ZCube created to sustain scientific and digital innovation, the latter being a great agent of change of our times especially in the healthcare sector."

The program is available through the website http://www.openaccelerator.it. A maximum of 30 projects will be selected to participate in the acceleration program that offers training andsupport by mentors and specialized advisors, including entrepreneurs, business angels, venture capitalists and experts from different areas.

The acceleration path is open to researchers and scientists that have the ambition to conduct translational science. The program will be based on the established methodology of the Business Model Canvas that has been adopted by the National Science Foundation (NSF) and the National Institute of Health (NIH) in the United States.

Moreover, ZCube has recently signed a partnership with IAB - Italian Angels for Biotech, the first association of business angels exclusively dedicated to Life Sciences- and Innogest, a leading venture capital fund operating in Italy and in Europe. Advisors from IAB and Innogest, along with other international experts, will participate in the acceleration path providing mentorship and advisory to guide startuppers through the business model creation and and go-to-market strategy development. At the end of the program the most innovative ideas could receive a seed investment of up to Euro 100.000, which will serve as an important catalyst to enter the market.

"Open Accelerator is an arena in which researchers and entrepreneurs are helped to build the foundation of their startups and to prepare for the challenge of reaching out to venture capital that will finance the next stages of their projects," concludes Elena Zambon. "Our accelerator program will become the heart of Open Zone, the scientific campus located near Milan where science oxygenates business. Open Zone is a community of 600 people where new projects, talents and proven expertise come together to help affirming the role of Italy as an ideal country for business innovation."

For further information and to apply, please visit:
http://www.openaccelerator.it

About ZCube Research Venture Zambon Group
For over a decade ZCube has been active in the exploration of innovative technologies with a profile of technology scouting & brokerage at international level. With an experienced team and network of entrepreneurs, business angels and venture capital, ZCube invests in- and supports innovative ideas from early stages of development up to market launch in the fields of drug delivery, medical devices and digital health. ZCube uses a satellite "open source" research model developed by Zambon in order to develop specialized and innovative products in the areas of the company’s therapeutic interest through collaborations with biotech companies, international research centers and universities.

About Open Zone
Open Zone is a scientific campus near Milan with over 7500mq of laboratories and offices 15.550mq, hosting 22 companies operating in the field of biotechnology and Life Sciences. Open Zone is a place where knowledge is shared amongst multiple partners in the life science to foster innovation, synergy and shared development as well as a place aimed at fostering the development of relationships with the community at large. Open Zone is also home to the Museum Zambon and Oxy.gen, a futuristic air-bubble shaped building created from an idea of the Zambon Group and designed by the architect Michele De Lucchi as a place of science associated with breathing.

About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women’s health, and is very strongly committed to its entry into the CNS space with Xadago® (safinamide) for the treatment of Parkinson’s disease and rare diseases with Promixin® in cystic fibrosis. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries and almost 2,800 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]